Sage Therapeutics Investigation: What Investors Should Know
The Law Offices of Frank R. Cruz are conducting an in-depth investigation into Sage Therapeutics, Inc. (NASDAQ: SAGE) on behalf of investors. The review focuses on potential violations of federal securities laws and whether recent events—and the company’s statements about them—left shareholders exposed to avoidable losses. If you own or owned SAGE shares and took a hit, this is aimed at protecting your interests.
Key Regulatory Decision and Market Response
On August 4, 2023, Sage Therapeutics announced the U.S. Food and Drug Administration’s (FDA) decision on its New Drug Application (NDA) for zuranolone, a treatment candidate for postpartum depression (PPD) and major depressive disorder (MDD). The FDA approved zuranolone for adults with PPD but issued a Complete Response Letter (CRL) for its use in adults with MDD, explaining that substantial evidence was lacking to support approval for that indication. Investors reacted swiftly to the split outcome, and the market response turned negative.
Impact of FDA Decision on Stock Performance
Following the FDA announcement, Sage’s stock dropped by $19.35, a 53.6% decline, closing at $16.75 on August 7, 2023. The move underscored how quickly regulatory news can reprice expectations, and how sensitive shares can be when a pivotal drug receives a limited approval and a CRL in the same breath.
Clinical Setbacks in 2024
Further challenges arrived in the months that followed. On April 17, 2024, Sage reported that a Phase 2 trial of SAGE-718—aimed at treating mild cognitive impairment due to Parkinson’s Disease—did not meet its primary endpoint. The update landed hard. Shares fell $3.06, or 19.6%, to close at $12.57 that day, reflecting renewed doubts about the company’s development pipeline.
Reactions to Recent Study Results
The SAGE-718 outcome led many investors to reassess their positions, particularly as it signaled a halt in the drug’s development for Parkinson’s Disease. With one less potential program moving forward, questions grew about near-term catalysts and the company’s path to future value creation.
Additional Trial Disclosures and Market Reactions
On July 24, 2024, Sage disclosed results from a Phase 2 trial of Sage-324 for essential tremor. The study did not show a statistically significant response compared with placebo, and the company announced it would not continue clinical development of Sage-324. The market response was immediate: the stock declined by $2.70, or 20.6%, closing at $10.38 per share.
Investor Sentiment and What Comes Next
A run of negative announcements has shaken confidence in Sage Therapeutics and sharpened focus on the company’s strategic direction. The cumulative impact of these developments has prompted some shareholders to evaluate their legal options. That’s where the investigation by The Law Offices of Frank R. Cruz comes in—assessing whether investors received full and fair information under federal securities laws.
Contact Information for Investors
If you purchased Sage Therapeutics stock or have information relevant to this investigation, consider reaching out to discuss your situation. Contact Frank R. Cruz at 310-914-5007 with questions or to share your experience. The Law Offices of Frank R. Cruz are located at 2121 Avenue of the Stars, Suite 800, Century City, California 90067.
Frequently Asked Questions
What is this investigation looking into?
The investigation examines potential violations of federal securities laws by Sage Therapeutics, including whether investors were adequately informed about developments that contributed to recent stock declines.
Which events triggered the sharp stock movements?
Key drivers included the August 4, 2023 FDA decision on zuranolone—approval for PPD but a CRL for MDD—followed by 2024 updates showing a failed primary endpoint for SAGE-718 and no significant benefit for Sage-324 versus placebo. Each announcement corresponded with a material drop in share price.
What should I do if I own or owned SAGE shares and lost money?
Consider contacting The Law Offices of Frank R. Cruz to discuss your circumstances and potential options. A brief call can help you understand next steps and whether your situation fits within the investigation’s scope.
Do I need to have a large position to participate?
No. Investors of all sizes who were affected by the stock declines can reach out. What matters is whether you were impacted by the events described and have information or records relevant to the investigation.
How can I get reliable updates without guesswork?
Review official company disclosures and speak directly with the legal team conducting the investigation. They can clarify what’s public, what’s being evaluated, and how it may relate to your holdings.
